Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance

被引:20
作者
Oikonomou, Evangelos [1 ]
Mourouzis, Konstantinos [1 ]
Fountoulakis, Petros [1 ]
Papamikroulis, Georgios Angelos [1 ]
Siasos, Gerasimos [1 ]
Antonopoulos, Alexis [1 ]
Vogiatzi, Georgia [1 ]
Tsalamadris, Sotiris [1 ]
Vavuranakis, Manolis [1 ]
Tousoulis, Dimitris [1 ]
机构
[1] Univ Athens, Hippokrat Hosp, Med Sch, Dept Cardiol 1, Vasilissis Sofias 114, Athens 11528, Greece
关键词
Heart failure; Diabetes mellitus; Systolic dysfunction; Diastolic dysfunction; Peroxisome proliferator-activated receptors; Thiazolidinediones; UBIQUITIN-PROTEASOME SYSTEM; ACUTE MYOCARDIAL-INFARCTION; GLYCATION END-PRODUCTS; ATTENUATES CARDIAC FIBROSIS; CORONARY-ARTERY-DISEASE; PPAR-GAMMA AGONISTS; ENDOPLASMIC-RETICULUM; DIASTOLIC FUNCTION; OXIDATIVE STRESS; FATTY-ACIDS;
D O I
10.1007/s10741-018-9682-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) is a common cardiac syndrome, whose pathophysiology involves complex mechanisms, some of which remain unknown. Diabetes mellitus (DM) constitutes not only a glucose metabolic disorder accompanied by insulin resistance but also a risk factor for cardiovascular disease and HF. During the last years though emerging data set up, a bidirectional interrelationship between these two entities. In the case of DM impaired calcium homeostasis, free fatty acid metabolism, redox state, and advance glycation end products may accelerate cardiac dysfunction. On the other hand, when HF exists, hypoperfusion of the liver and pancreas, b-blocker and diuretic treatment, and autonomic nervous system dysfunction may cause impairment of glucose metabolism. These molecular pathways may be used as therapeutic targets for novel antidiabetic agents. Peroxisome proliferator-activated receptors (PPARs) not only improve insulin resistance and glucose and lipid metabolism but also manifest a diversity of actions directly or indirectly associated with systolic or diastolic performance of left ventricle and symptoms of HF. Interestingly, they may beneficially affect remodeling of the left ventricle, fibrosis, and diastolic performance but they may cause impaired water handing, sodium retention, and decompensation of HF which should be taken into consideration in the management of patients with DM. In this review article, we present the pathophysiological data linking HF with DM and we focus on the molecular mechanisms of PPARs agonists in left ventricle systolic and diastolic performance providing useful insights in the molecular mechanism of this class of metabolically active regiments.
引用
收藏
页码:389 / 408
页数:20
相关论文
共 50 条
  • [21] Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose - Role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression
    Sartippour, MR
    Renier, G
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) : 104 - 110
  • [22] Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
    Lee, Wang-Soo
    Kim, Jaetaek
    PPAR RESEARCH, 2015, 2015
  • [23] Effect of Pesticides on Peroxisome Proliferator-Activated Receptors (PPARs) and Their Association with Obesity and Diabetes
    Hernandez-Valdez, J.
    Velazquez-Zepeda, A.
    Sanchez-Meza, J. C.
    PPAR RESEARCH, 2023, 2023
  • [24] Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart
    Lee, Ting-I
    Kao, Yu-Hsun
    Chen, Yao-Chang
    Pan, Nan-Hung
    Chen, Yi-Jen
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (08) : 692 - 699
  • [25] Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection
    Barlaka, Eleftheria
    Galatou, Eleftheria
    Mellidis, Kyriakos
    Ravingerova, Tanya
    Lazou, Antigone
    CARDIOVASCULAR THERAPEUTICS, 2016, 34 (01) : 37 - 48
  • [26] Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease
    Giby, Vettickattuparambil George
    Ajith, Thekkuttuparambil Ananthanarayanan
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (08) : 570 - 579
  • [27] The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
    Tyagi, Sandeep
    Gupta, Paras
    Saini, Arminder Singh
    Kaushal, Chaitnya
    Sharma, Saurabh
    JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH, 2011, 2 (04) : 236 - 240
  • [28] Peroxisome proliferator-activated receptors-alpha (PPAR-α) and chronic heart failure: Is there a reason to discuss the metabolic strategy of treatment?
    Zhirov, I. V.
    Zaseyeva, A. V.
    Masenko, V. P.
    Tereshchenko, S. N.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (01) : 78 - 82
  • [29] Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
    Melis, Miriam
    Carta, Gianfranca
    Pistis, Marco
    Banni, Sebastiano
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (01) : 70 - 77
  • [30] Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure
    Lkhagva, Baigalmaa
    Lin, Yung-Kuo
    Kao, Yu-Hsun
    Chazo, Tze-Fan
    Chung, Cheng-Chih
    Chen, Shih-Ann
    Chen, Yi-Jen
    PHARMACOLOGY, 2015, 96 (3-4) : 184 - 191